- Home
- OCG vs IGC Comparison
OCG vs IGC Comparison
Compare OCG & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCG
- IGC
- Stock Information
- Founded
- OCG 2018
- IGC 2005
- Country
- OCG Hong Kong
- IGC United States
- Employees
- OCG N/A
- IGC N/A
- Industry
- OCG Other Consumer Services
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- OCG Consumer Discretionary
- IGC Health Care
- Exchange
- OCG Nasdaq
- IGC Nasdaq
- Market Cap
- OCG 25.1M
- IGC 26.9M
- IPO Year
- OCG 2020
- IGC N/A
- Fundamental
- Price
- OCG $1.32
- IGC $0.38
- Analyst Decision
- OCG
- IGC Strong Buy
- Analyst Count
- OCG 0
- IGC 2
- Target Price
- OCG N/A
- IGC $3.75
- AVG Volume (30 Days)
- OCG 25.9K
- IGC 465.1K
- Earning Date
- OCG 12-24-2024
- IGC 02-12-2025
- Dividend Yield
- OCG N/A
- IGC N/A
- EPS Growth
- OCG N/A
- IGC N/A
- EPS
- OCG N/A
- IGC N/A
- Revenue
- OCG $1,227,855.00
- IGC $1,183,000.00
- Revenue This Year
- OCG N/A
- IGC N/A
- Revenue Next Year
- OCG N/A
- IGC $13.57
- P/E Ratio
- OCG N/A
- IGC N/A
- Revenue Growth
- OCG N/A
- IGC N/A
- 52 Week Low
- OCG $0.91
- IGC $0.25
- 52 Week High
- OCG $2.60
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- OCG 48.48
- IGC 50.02
- Support Level
- OCG $1.13
- IGC $0.35
- Resistance Level
- OCG $1.92
- IGC $0.40
- Average True Range (ATR)
- OCG 0.18
- IGC 0.03
- MACD
- OCG -0.01
- IGC 0.00
- Stochastic Oscillator
- OCG 20.00
- IGC 32.71
About OCG Oriental Culture Holding LTD
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance service to customers in China and Hong Kong. It operates through one segment namely, e-commerce of artwork trading. It generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.